Citadel Advisors
BLRX

Citadel Advisors’s BioLineRX BLRX Stock Holding History

Citadel Advisors’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,600
Closed -$33.1K – 13012
2025
Q4 		$33.1K Buy
+11,600
New +$40.1K ﹤0.01% 12195
2025
Q3 		– Sell
-43,500
Closed -$199K – 12786
2025
Q2 		$199K Buy
+43,500
New +$161K ﹤0.01% 10689
2025
Q1 		– Sell
-1,878
Closed -$16K – 14504
2024
Q4 		$16K Buy
1,878
+715
+61% +$10.5K ﹤0.01% 13331
2024
Q3 		$24.9K Sell
1,163
-85
-7% -$2.33K ﹤0.01% 12606
2024
Q2 		$28.2K Buy
1,248
+645
+107% +$17.3K ﹤0.01% 12327
2024
Q1 		$27K Sell
603
-307
-34% -$15.4K ﹤0.01% 12788
2023
Q4 		$57.1K Sell
910
-1,568
-63% -$97K ﹤0.01% 11641
2023
Q3 		$180K Buy
2,478
+1,358
+121% +$91.3K ﹤0.01% 10089
2023
Q2 		$71.5K Buy
+1,120
New +$62K ﹤0.01% 11369
2022
Q3 		– Sell
-258
Closed -$13K – 12630
2022
Q2 		$13K Sell
258
-17
-6% -$945 ﹤0.01% 12520
2022
Q1 		$19K Sell
275
-253
-48% -$17.6K ﹤0.01% 13250
2021
Q4 		$43K Buy
+528
New +$55K ﹤0.01% 13322
2021
Q3 		– Sell
-688
Closed -$77K – 13806
2021
Q2 		$77K Buy
+688
New +$80.9K ﹤0.01% 13098

Other funds holding BLRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citadel Advisors's BLRX Position: Q1 2026 in Review

Citadel Advisors sold out of BioLineRX (BLRX) in Q1 2026, closing a stake of 36,651 shares — an estimated $104K sold.

Citadel Advisors first reported a position in BLRX in Q1 2014 and held it in 20 quarters. The position peaked at $451K in Q3 2021. 13 funds tracked by Wall St. Rank hold BLRX as of Q1 2026.

  • Citadel Advisors reported no remaining BioLineRX position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 36,651 BioLineRX shares in Q1 2026, an estimated $104K.
  • Citadel Advisors first reported a position in BioLineRX in Q1 2014 and held it in 20 quarters.
  • Citadel Advisors's BioLineRX position peaked at $451K in Q3 2021.
  • 13 funds tracked by Wall St. Rank held BioLineRX as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.